Advicenne Stock

ALDVI

FR0013296746

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 04/08/2026 +04			5-day change	1st Jan Change
1.640 ^EUR	+0.37%		+2.50%	-5.20%

07-21	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
07-16	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI

Analysts' recommendations: Advicenne

19/09/24

Advicenne: TP ICAP Midcap lowers its target

More recommendations

News in other languages: Advicenne

07-20	Le produit phare d'Advicenne remboursé en Espagne
07-20	Advicenne annonce le remboursement de Sibnayal® dans le traitement de l’ATRd en Espagne
07-16	Advicenne : Le chiffre d’affaires net du premier semestre 2026 porté par le remboursement de Sibnayal® et Likozam® en France
07-01	Advicenne annonce le renouvellement illimité de l’Autorisation de Mise sur le Marché de Sibnayal® au Royaume-Uni
06-23	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

More news

Managers and Directors: Advicenne

Manager	Title	Age	Since
Didier Laurens CEO	Chief Executive Officer	59	03/05/2021
Delphine Dumas CTO	Chief Tech/Sci/R&D Officer	-	01/09/2025
Véronique Leblanc CTO	Chief Tech/Sci/R&D Officer	-	01/04/2023

Director	Title	Age	Since
André Ulmann BRD	Director/Board Member	-	23/06/2017
Catherine Dunand BRD	Director/Board Member	64	09/03/2017
Charlotte Sibley BRD	Director/Board Member	78	20/09/2018

More insiders

Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2025, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Employees

Sector

Pharmaceuticals

Calendar

09-17 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
04/08/26	€1.640	+0.37%	69,267
03/08/26	€1.634	-0.37%	70,306
31/07/26	€1.640	-5.96%	81,494
30/07/26	€1.744	+4.43%	116,949
29/07/26	€1.670	+4.37%	58,401

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.640EUR

Average target price

4.000EUR

Spread / Average Target

+143.90%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Stock Market
Stocks
ALDVI Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	23.86M 27.48M 22.25M 20.44M 38.65M 2.61B 39.07M 262M 103M 1.31B 103M 101M 4.33B	P/E 2026 *	-3.49x	P/E 2027 *	-3.73x
Enterprise Value	46.96M 54.08M 43.78M 40.22M 76.07M 5.14B 76.9M 516M 202M 2.57B 203M 199M 8.52B	EV / Sales 2026 *	7.11x	EV / Sales 2027 *	6.63x
Free-Float	95.15%	Yield 2026 *	-	Yield 2027 *	-

07-21	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
07-16	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI
07-02	UK Regulator Grants 'Unlimited Renewal' of Advicenne's Distal Renal Tubular Acidosis Drug	MT
07-01	Advicenne Announces Unlimited Renewal of Marketing Authorization for Sibnayal in United Kingdom	CI
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne Raises EUR4 Million from Two-tranche Bonds Issuance	MT
06-22	Advicenne S.A. Secures Its Cash Runway to Second Quarter 2027 Through A Bond Financing of A Nominal Amount of Up to EUR 3.8 Million	CI
06-01	Advicenne soars as Likozam secures social security reimbursement
06-01	Advicenne's Likozam added to France's list of reimbursable medicines
05-21	Advicenne S.A. Announces Board Changes	CI
05-06	Investors Can't Get Enough of Chips
04-24	Advicenne S.A. Auditor Raises 'Going Concern' Doubt	CI

1 day	+0.37%
1 week	+2.50%
1 month	+17.14%
3 months	+33.33%
6 months	-14.58%
Current year	-5.20%

1 week	1.62	1.82
1 month	1.43	2.21
Current year	0.8	2.35
1 year	0.8	2.35
3 years	0.8	3.5
5 years	0.8	10.5
10 years	0.8	16.25

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/12/20	Nathalie Lemarié	Sell	General Counsel	998	0.0123%
29/12/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%
25/12/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%

Advicenne Stock

Stocks

ALDVI

FR0013296746

Pharmaceuticals

Valuation: Advicenne

Chart: Advicenne

Latest news : Advicenne

Analysts' recommendations: Advicenne

Press Releases: Advicenne

News in other languages: Advicenne

Quotes and Performance

Course Extremes

Managers and Directors: Advicenne

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

07-20	Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain	BU
07-16	Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France	BU
07-01	Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom	BU
06-23	Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million	AQ
06-22	Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADVICENNE	+0.37%	+2.50%	+41.38%	-51.91%	27.35M
REGENERON PHARMACEUTICALS, INC.	+0.19%	+9.42%	+33.09%	-0.75%	75.81B
UCB	+0.86%	-10.75%	+20.93%	+180.67%	48.57B
SAMSUNG BIOLOGICS CO.,LTD.	+3.72%	-4.71%	-8.40%	+20.60%	46.01B
CSL LIMITED	+1.01%	+1.58%	-51.31%	-50.38%	41.66B
BIOGEN INC.	+3.29%	+1.38%	+57.68%	-22.49%	29.82B
INCYTE CORPORATION	+1.83%	-7.18%	+54.54%	+89.53%	24.01B
MODERNA, INC.	+3.36%	+2.12%	+106.19%	-47.32%	22.01B
INNOVENT BIOLOGICS, INC.	+2.48%	-3.56%	-6.67%	+164.33%	19.09B
SWEDISH ORPHAN BIOVITRUM AB	+0.05%	-6.56%	+61.68%	+115.73%	15.83B
Average	+1.55%	-0.57%	+30.91%	+39.80%	32.28B
Weighted average by Cap.	+1.55%	+0.66%	+22.36%	+40.18%

	2026 *	2027 *
Net sales	6.6M 7.6M 6.15M 5.65M 10.69M 723M 10.81M 72.55M 28.36M 361M 28.54M 27.92M 1.2B	8M 9.21M 7.46M 6.85M 12.96M 876M 13.1M 87.94M 34.38M 438M 34.6M 33.84M 1.45B
Net income	-6.7M -7.72M -6.25M -5.74M -10.85M -734M -10.97M -73.65M -28.79M -367M -28.98M -28.34M -1.22B	-6.2M -7.14M -5.78M -5.31M -10.04M -679M -10.15M -68.15M -26.64M -340M -26.81M -26.23M -1.13B
Net Debt	23.1M 26.6M 21.54M 19.79M 37.42M 2.53B 37.83M 254M 99.26M 1.27B 99.9M 97.72M 4.19B	29.2M 33.63M 27.23M 25.01M 47.3M 3.2B 47.82M 321M 125M 1.6B 126M 124M 5.3B